The Milpitas, California-based company received FDA clearance for its diabetes management platform in May 2021. Its initial rollout featured compatibility with iOS devices. The first-of-its-kind system includes connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy.
Bigfoot’s smart pen caps offer on-demand insulin dose decision support. This helps to minimize guesswork and help patients to follow their doctors’ instructions. Additionally, the caps have compatibility with a broad range of disposable insulin pens for both long-acting and rapid-acting insulin.
Get the full story at our sister site, Drug Delivery Business News.